ZYBERNO
Stock Report
Updated Aug 23, 2026

NUCANA PLC (NCNA)

Healthcare • NASDAQ

$1.52

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
NUCANA PLC (NCNA) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-19,845.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

NUCANA PLC (NCNA) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.52
Market Cap:$5.89M

Valuation Multiples (2)

P/B Ratio:0.18x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$26.80M

Price Action & Momentum (1)

% of 52-Week High:21.1%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-360.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.60x
Quick Ratio:5.60x
Cash Ratio:5.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.59x
Times Interest Earned:-1.59

Capital Structure (4)

Working Capital:29,744,949.64
Cash And Cash Equivalents:32,687,365.13
Long Term Debt:$0.00
Net Debt:-$32.69M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$27.11M

Bottom Line Performance (3)

-$39.56M
Income Before Tax:$0.00
Ebitda Ttm:-26,736,488.17

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$4.69M
Interest Expense:17,047,948.30

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$40.21M
Current Assets:$36.21M
Ppe Net:886,903.07
Goodwill:0.00
Intangible Assets:$2.96M

Liability Structure (4)

Total Liabilities:7,422,758.64
Current Liabilities:6,460,374.46
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$32.79M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:1,144,347.57
Inventory:0.00
Accounts Payable:703,591.79

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.06M-$10.06M

Investment Activities (1)

Investing Cash Flow:-$159.05K

Financing Activities (3)

Financing Cash Flow:$167.14K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$10.21

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.60

Book Value & Capital (2)

Book Value Per Share:$8.46
Cash Per Share:8.44

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-360.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:NCNA
Company Name:NUCANA PLC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United Kingdom

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.87M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 04:02:43 UTC
Data Timestamp:2026-08-21T20:35:28.817163
Scroll to Top